Strength: 10 mg
Form: Oral tablets
Reference Brands: Hepsera® (EU & US)
Strength: 25 mg TAF per tablet
Form: Tablet
Reference Brands: Vemlidy (EU & US), Genvoya (India)
Strength: 300 mg
Reference Brands: Viread (EU & US), Truvada (India)
Strength: 100 mg, 150 mg, 300 mg
Reference Brands: Epivir®, Epivir-HBV® (US & EU)
Strength: 100 IU or 500 IU per vial/ampoule
Form: Injection
Reference Brands: HepaGam B®, Nabi-HB®, HyperHEP B®(US); Hepatect CP, Zutectra®, HBIG Bayer®, Beriglobin® P(EU)
Strength: Diph. toxoid: ≥ 30 International Units ; Tetanus toxoid: ≥ 40 International Units
Reference Brands: Daptacel®, Infanrix®(US); Boostrix® ,Tripedia® (EU)
Strength: 120 mcg, 150 mcg, 180 mcg
Reference Brands: Pegasys® (US & EU), PegIntron® (EU)
Strength: 30 mg, 60 mg
Reference Brands: Daklinza® (US & EU)
Strength: Daclatasvir 60 mg + Sofosbuvir 400 mg
Reference Brands: Hepcinat Plus (India), Myhep Dvir (India)
Strength: IVIG: 5%, 10%, 16%, 20%; SCIG: 20%
Form: (IVIG) & (SCIG)
Reference Brands: Privigen®, Gamunex-C® (EU & US),Flebogamma (LATAM)
Strength: 3 million IU/vial, 5 million IU/vial, 10 million IU/vial
Form: Lyophilized Powder for Injection
Reference Brands: Intron A® (EU & US), Roferon-A®(EU), Virafin (Indila)
Strength: 400 mg
Form: Film-coated Tablets
Reference Brands: Sovaldi® (EU & US)
Strength: 1.6 mg/vial
Reference Brands: Zadaxin® (EU & US)
Strength: Tablet: 25 mg, 50 mg, 75 mg; Suspension: 12.5 mg/5 mL
Form: Tablets & Oral suspension
Reference Brands: Promacta® (US & EU); Revolade®(EU)
Strength: Sofosbuvir 400 mg + Velpatasvir 100 mg
Reference Brands: Epclusa (EU & US), Velpanat (india)
Strength: 0.5 mg, 1 mg
Reference Brands: Baraclude® (EU & US)
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Reference Brands: Sutent® (EU & US)
Strength: 1 g/vial,2 g/vial, 3 g/vial
Reference Brands: Ifex® (US), Holoxan® (EU)
Strength: 20 mg/0.5 mL, 80 mg/2 mL, 160 mg/4 mL
Reference Brands: Taxotere (US & EU)
Strength: Capsule:140 mg, 70 mg; Tablet: 140 mg
Form: Capsules and tablets
Reference Brands: Imbruvica®(US & EU)
Stay updated on pharma trends and marketplace opportunities.